nodes	percent_of_prediction	percent_of_DWPC	metapath
Icosapent—PPARG—psoriasis	0.715	1	CbGaD
Icosapent—PTGS2—Triamcinolone—psoriasis	0.0393	0.424	CbGbCtD
Icosapent—PTGS2—Betamethasone—psoriasis	0.0337	0.364	CbGbCtD
Icosapent—PTGS2—Dexamethasone—psoriasis	0.0196	0.212	CbGbCtD
Icosapent—PPARG—dermis—psoriasis	0.00864	0.266	CbGeAlD
Icosapent—PTGS2—skeletal joint—psoriasis	0.00381	0.117	CbGeAlD
Icosapent—PTGS2—synovial membrane of synovial joint—psoriasis	0.00289	0.0891	CbGeAlD
Icosapent—PPARG—endothelium—psoriasis	0.00264	0.0812	CbGeAlD
Icosapent—FADS1—tendon—psoriasis	0.0021	0.0646	CbGeAlD
Icosapent—ACSL4—tendon—psoriasis	0.0019	0.0587	CbGeAlD
Icosapent—PTGS2—skin epidermis—psoriasis	0.00186	0.0572	CbGeAlD
Icosapent—PPARD—tendon—psoriasis	0.00183	0.0563	CbGeAlD
Icosapent—Aspartate aminotransferase increased—Calcitriol—psoriasis	0.0015	0.0194	CcSEcCtD
Icosapent—Oropharyngeal pain—Mycophenolic acid—psoriasis	0.00148	0.0191	CcSEcCtD
Icosapent—Pruritus—Calcipotriol—psoriasis	0.00146	0.0189	CcSEcCtD
Icosapent—PTGS1—endothelium—psoriasis	0.00141	0.0434	CbGeAlD
Icosapent—PTGS2—endothelium—psoriasis	0.00135	0.0415	CbGeAlD
Icosapent—Eructation—Mycophenolic acid—psoriasis	0.00132	0.0171	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Acitretin—psoriasis	0.00131	0.0169	CcSEcCtD
Icosapent—Rash—Calcipotriol—psoriasis	0.0013	0.0168	CcSEcCtD
Icosapent—Dermatitis—Calcipotriol—psoriasis	0.0013	0.0168	CcSEcCtD
Icosapent—Anaphylactic shock—Beclomethasone—psoriasis	0.00118	0.0152	CcSEcCtD
Icosapent—PPARG—skin of body—psoriasis	0.00113	0.0347	CbGeAlD
Icosapent—Dysgeusia—Methoxsalen—psoriasis	0.0011	0.0143	CcSEcCtD
Icosapent—Pruritus—Tazarotene—psoriasis	0.00108	0.0139	CcSEcCtD
Icosapent—Eructation—Cyclosporine—psoriasis	0.00107	0.0138	CcSEcCtD
Icosapent—Eructation—Mycophenolate mofetil—psoriasis	0.00104	0.0135	CcSEcCtD
Icosapent—Oropharyngeal pain—Triamcinolone—psoriasis	0.001	0.0129	CcSEcCtD
Icosapent—Dysgeusia—Calcitriol—psoriasis	0.000983	0.0127	CcSEcCtD
Icosapent—Rash—Tazarotene—psoriasis	0.000961	0.0124	CcSEcCtD
Icosapent—Dermatitis—Tazarotene—psoriasis	0.00096	0.0124	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Clobetasol propionate—psoriasis	0.000929	0.157	CbGdCrCtD
Icosapent—Pruritus—Clobetasol propionate—psoriasis	0.000914	0.0118	CcSEcCtD
Icosapent—Malnutrition—Fluocinolone Acetonide—psoriasis	0.000891	0.0115	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Mycophenolic acid—psoriasis	0.000878	0.0114	CcSEcCtD
Icosapent—Dysgeusia—Acitretin—psoriasis	0.000875	0.0113	CcSEcCtD
Icosapent—Dysgeusia—Fluocinolone Acetonide—psoriasis	0.000872	0.0113	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Mycophenolic acid—psoriasis	0.00086	0.0111	CcSEcCtD
Icosapent—PPARG—tendon—psoriasis	0.000857	0.0264	CbGeAlD
Icosapent—Pruritus—Fluocinonide—psoriasis	0.000824	0.0107	CcSEcCtD
Icosapent—Anaphylactic shock—Calcitriol—psoriasis	0.00082	0.0106	CcSEcCtD
Icosapent—Rash—Clobetasol propionate—psoriasis	0.000814	0.0105	CcSEcCtD
Icosapent—Dermatitis—Clobetasol propionate—psoriasis	0.000814	0.0105	CcSEcCtD
Icosapent—Dyspepsia—Methoxsalen—psoriasis	0.000809	0.0105	CcSEcCtD
Icosapent—Gastrointestinal disorder—Methoxsalen—psoriasis	0.000794	0.0103	CcSEcCtD
Icosapent—Arthralgia—Acitretin—psoriasis	0.000761	0.00983	CcSEcCtD
Icosapent—Arthralgia—Fluocinolone Acetonide—psoriasis	0.000758	0.00981	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Calcitriol—psoriasis	0.000747	0.00965	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Beclomethasone—psoriasis	0.000744	0.126	CbGdCrCtD
Icosapent—Rash—Beclomethasone—psoriasis	0.000741	0.00959	CcSEcCtD
Icosapent—Dermatitis—Beclomethasone—psoriasis	0.000741	0.00958	CcSEcCtD
Icosapent—Rash—Fluocinonide—psoriasis	0.000735	0.0095	CcSEcCtD
Icosapent—Dermatitis—Fluocinonide—psoriasis	0.000734	0.00949	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Fluocinolone Acetonide—psoriasis	0.000723	0.122	CbGdCrCtD
Icosapent—Constipation—Calcitriol—psoriasis	0.000701	0.00906	CcSEcCtD
Icosapent—Aspartate aminotransferase increased—Mycophenolate mofetil—psoriasis	0.000693	0.00896	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Mycophenolate mofetil—psoriasis	0.000679	0.00878	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Acitretin—psoriasis	0.000664	0.00859	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Fluocinolone Acetonide—psoriasis	0.000662	0.00857	CcSEcCtD
Icosapent—Pruritus—Methoxsalen—psoriasis	0.000651	0.00841	CcSEcCtD
Icosapent—Dyspepsia—Acitretin—psoriasis	0.000642	0.0083	CcSEcCtD
Icosapent—Gastrointestinal disorder—Acitretin—psoriasis	0.000629	0.00814	CcSEcCtD
Icosapent—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000628	0.00812	CcSEcCtD
Icosapent—Constipation—Acitretin—psoriasis	0.000623	0.00806	CcSEcCtD
Icosapent—Alanine aminotransferase increased—Hydrocortisone—psoriasis	0.000619	0.008	CcSEcCtD
Icosapent—PPARG—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.00061	0.00799	CbGpPWpGaD
Icosapent—PTGS1—skin of body—psoriasis	0.000602	0.0185	CbGeAlD
Icosapent—FADS1—PPARA activates gene expression—PPARG—psoriasis	0.000599	0.00784	CbGpPWpGaD
Icosapent—Malnutrition—Mycophenolic acid—psoriasis	0.000587	0.0076	CcSEcCtD
Icosapent—FADS1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	0.000586	0.00768	CbGpPWpGaD
Icosapent—PPARD—NRF2 pathway—TGFA—psoriasis	0.000583	0.00764	CbGpPWpGaD
Icosapent—Pruritus—Calcitriol—psoriasis	0.00058	0.0075	CcSEcCtD
Icosapent—Rash—Methoxsalen—psoriasis	0.00058	0.0075	CcSEcCtD
Icosapent—Dermatitis—Methoxsalen—psoriasis	0.000579	0.00749	CcSEcCtD
Icosapent—PTGS2—skin of body—psoriasis	0.000575	0.0177	CbGeAlD
Icosapent—PPARD—Nuclear Receptor transcription pathway—PPARG—psoriasis	0.000563	0.00737	CbGpPWpGaD
Icosapent—PTGS2—Fluticasone Propionate—Clobetasol propionate—psoriasis	0.00056	0.0948	CbGdCrCtD
Icosapent—PPARG—Nuclear Receptors—VDR—psoriasis	0.000558	0.00731	CbGpPWpGaD
Icosapent—PTGS1—Overview of nanoparticle effects—CRP—psoriasis	0.000557	0.00729	CbGpPWpGaD
Icosapent—FFAR1—GPCR downstream signaling—HCAR2—psoriasis	0.000549	0.00719	CbGpPWpGaD
Icosapent—PPARG—Transcriptional regulation of white adipocyte differentiation—CARM1—psoriasis	0.000531	0.00696	CbGpPWpGaD
Icosapent—Vomiting—Calcitriol—psoriasis	0.000521	0.00674	CcSEcCtD
Icosapent—Rash—Calcitriol—psoriasis	0.000517	0.00668	CcSEcCtD
Icosapent—Dermatitis—Calcitriol—psoriasis	0.000516	0.00668	CcSEcCtD
Icosapent—Pruritus—Acitretin—psoriasis	0.000516	0.00667	CcSEcCtD
Icosapent—Pruritus—Fluocinolone Acetonide—psoriasis	0.000514	0.00665	CcSEcCtD
Icosapent—PPARD—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.000513	0.00671	CbGpPWpGaD
Icosapent—FFAR1—GPCR ligand binding—CCL20—psoriasis	0.000505	0.00661	CbGpPWpGaD
Icosapent—Dyspepsia—Hydroxyurea—psoriasis	0.000504	0.00652	CcSEcCtD
Icosapent—Arthralgia—Mycophenolic acid—psoriasis	0.0005	0.00647	CcSEcCtD
Icosapent—FFAR1—Signaling by GPCR—HCAR2—psoriasis	0.000499	0.00653	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—NDUFA5—psoriasis	0.000495	0.00648	CbGpPWpGaD
Icosapent—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000494	0.00639	CcSEcCtD
Icosapent—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000493	0.00646	CbGpPWpGaD
Icosapent—Constipation—Hydroxyurea—psoriasis	0.000489	0.00633	CcSEcCtD
Icosapent—ACSL3—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000482	0.00631	CbGpPWpGaD
Icosapent—Malnutrition—Cyclosporine—psoriasis	0.000475	0.00614	CcSEcCtD
Icosapent—Dysgeusia—Cyclosporine—psoriasis	0.000465	0.00602	CcSEcCtD
Icosapent—Malnutrition—Mycophenolate mofetil—psoriasis	0.000464	0.00599	CcSEcCtD
Icosapent—Vomiting—Acitretin—psoriasis	0.000464	0.00599	CcSEcCtD
Icosapent—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.000463	0.00605	CbGpPWpGaD
Icosapent—Vomiting—Fluocinolone Acetonide—psoriasis	0.000462	0.00598	CcSEcCtD
Icosapent—ACSL3—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000461	0.00604	CbGpPWpGaD
Icosapent—Alanine aminotransferase increased—Prednisone—psoriasis	0.00046	0.00595	CcSEcCtD
Icosapent—Rash—Acitretin—psoriasis	0.00046	0.00594	CcSEcCtD
Icosapent—Dermatitis—Acitretin—psoriasis	0.000459	0.00594	CcSEcCtD
Icosapent—Rash—Fluocinolone Acetonide—psoriasis	0.000458	0.00593	CcSEcCtD
Icosapent—PTGS1—tendon—psoriasis	0.000458	0.0141	CbGeAlD
Icosapent—Dermatitis—Fluocinolone Acetonide—psoriasis	0.000458	0.00592	CcSEcCtD
Icosapent—Dysgeusia—Mycophenolate mofetil—psoriasis	0.000454	0.00587	CcSEcCtD
Icosapent—PTGS2—Fluticasone Propionate—Beclomethasone—psoriasis	0.000449	0.076	CbGdCrCtD
Icosapent—PTGS2—Fluticasone Propionate—Fluocinonide—psoriasis	0.000449	0.076	CbGdCrCtD
Icosapent—PTGS2—Overview of nanoparticle effects—CRP—psoriasis	0.000442	0.00579	CbGpPWpGaD
Icosapent—PPARG—Nuclear Receptor transcription pathway—VDR—psoriasis	0.000441	0.00577	CbGpPWpGaD
Icosapent—PTGS2—tendon—psoriasis	0.000438	0.0135	CbGeAlD
Icosapent—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000437	0.00565	CcSEcCtD
Icosapent—PTGS2—Fluticasone Propionate—Fluocinolone Acetonide—psoriasis	0.000436	0.0738	CbGdCrCtD
Icosapent—PPARD—Presenilin action in Notch and Wnt signaling—JUN—psoriasis	0.000434	0.00568	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000424	0.00555	CbGpPWpGaD
Icosapent—Malnutrition—Hydrocortisone—psoriasis	0.000422	0.00546	CcSEcCtD
Icosapent—Dyspepsia—Mycophenolic acid—psoriasis	0.000422	0.00546	CcSEcCtD
Icosapent—ACSL3—Metabolism—CYP2S1—psoriasis	0.000421	0.00551	CbGpPWpGaD
Icosapent—FADS1—Metabolism—NDUFA5—psoriasis	0.000415	0.00543	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—SOCS1—psoriasis	0.000415	0.00543	CbGpPWpGaD
Icosapent—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000414	0.00535	CcSEcCtD
Icosapent—Constipation—Mycophenolic acid—psoriasis	0.00041	0.0053	CcSEcCtD
Icosapent—Arthralgia—Cyclosporine—psoriasis	0.000405	0.00523	CcSEcCtD
Icosapent—FADS1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000404	0.00529	CbGpPWpGaD
Icosapent—PTGS1—Biological oxidations—CYP2S1—psoriasis	0.000401	0.00525	CbGpPWpGaD
Icosapent—PPARG—PPARA activates gene expression—CARM1—psoriasis	0.000399	0.00523	CbGpPWpGaD
Icosapent—Arthralgia—Mycophenolate mofetil—psoriasis	0.000395	0.0051	CcSEcCtD
Icosapent—PPARG—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	0.000391	0.00512	CbGpPWpGaD
Icosapent—Dysgeusia—Triamcinolone—psoriasis	0.000389	0.00504	CcSEcCtD
Icosapent—Anaphylactic shock—Cyclosporine—psoriasis	0.000388	0.00502	CcSEcCtD
Icosapent—FADS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000387	0.00506	CbGpPWpGaD
Icosapent—SLC8A1—Hemostasis—ITGAL—psoriasis	0.000385	0.00503	CbGpPWpGaD
Icosapent—Anaphylactic shock—Mycophenolate mofetil—psoriasis	0.000378	0.00489	CcSEcCtD
Icosapent—ACSL4—Metabolism—NDUFA5—psoriasis	0.000375	0.00491	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—NDUFA5—psoriasis	0.000375	0.00491	CbGpPWpGaD
Icosapent—FFAR1—Metabolism of proteins—REN—psoriasis	0.000372	0.00487	CbGpPWpGaD
Icosapent—ACSL4—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000365	0.00478	CbGpPWpGaD
Icosapent—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—psoriasis	0.000365	0.00477	CbGpPWpGaD
Icosapent—Vomiting—Hydroxyurea—psoriasis	0.000364	0.00471	CcSEcCtD
Icosapent—PTGS1—Overview of nanoparticle effects—CXCL8—psoriasis	0.000362	0.00474	CbGpPWpGaD
Icosapent—Rash—Hydroxyurea—psoriasis	0.000361	0.00467	CcSEcCtD
Icosapent—Dermatitis—Hydroxyurea—psoriasis	0.000361	0.00466	CcSEcCtD
Icosapent—PPARD—Gene Expression—TARS—psoriasis	0.000358	0.00468	CbGpPWpGaD
Icosapent—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000353	0.00457	CcSEcCtD
Icosapent—Anaphylactic shock—Prednisolone—psoriasis	0.000353	0.00456	CcSEcCtD
Icosapent—FADS1—Metabolism—CYP2S1—psoriasis	0.000352	0.00461	CbGpPWpGaD
Icosapent—ACSL4—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.00035	0.00458	CbGpPWpGaD
Icosapent—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000345	0.00446	CcSEcCtD
Icosapent—Anaphylactic shock—Hydrocortisone—psoriasis	0.000345	0.00446	CcSEcCtD
Icosapent—Dyspepsia—Cyclosporine—psoriasis	0.000341	0.00441	CcSEcCtD
Icosapent—Pruritus—Mycophenolic acid—psoriasis	0.000339	0.00439	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Dexamethasone—psoriasis	0.000339	0.0574	CbGdCrCtD
Icosapent—PTGS2—Fluocinonide—Betamethasone—psoriasis	0.000339	0.0574	CbGdCrCtD
Icosapent—Gastrointestinal disorder—Cyclosporine—psoriasis	0.000335	0.00433	CcSEcCtD
Icosapent—Dyspepsia—Mycophenolate mofetil—psoriasis	0.000333	0.00431	CcSEcCtD
Icosapent—Constipation—Cyclosporine—psoriasis	0.000332	0.00429	CcSEcCtD
Icosapent—PTGS2—Fluocinonide—Triamcinolone—psoriasis	0.000331	0.0561	CbGdCrCtD
Icosapent—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000327	0.00422	CcSEcCtD
Icosapent—Anaphylactic shock—Triamcinolone—psoriasis	0.000325	0.0042	CcSEcCtD
Icosapent—Constipation—Mycophenolate mofetil—psoriasis	0.000324	0.00418	CcSEcCtD
Icosapent—SLC8A1—Transmembrane transport of small molecules—CP—psoriasis	0.000322	0.00421	CbGpPWpGaD
Icosapent—PPARG—Transcription factor regulation in adipogenesis—TNF—psoriasis	0.00032	0.00419	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—CYP2S1—psoriasis	0.000319	0.00417	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—CYP2S1—psoriasis	0.000319	0.00417	CbGpPWpGaD
Icosapent—Malnutrition—Prednisone—psoriasis	0.000314	0.00406	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000314	0.00406	CcSEcCtD
Icosapent—TRPV1—Transmembrane transport of small molecules—CP—psoriasis	0.000311	0.00407	CbGpPWpGaD
Icosapent—SLC8A1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000307	0.00402	CbGpPWpGaD
Icosapent—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000307	0.00401	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—LEP—psoriasis	0.000306	0.004	CbGpPWpGaD
Icosapent—Vomiting—Mycophenolic acid—psoriasis	0.000305	0.00394	CcSEcCtD
Icosapent—Dyspepsia—Hydrocortisone—psoriasis	0.000303	0.00392	CcSEcCtD
Icosapent—Rash—Mycophenolic acid—psoriasis	0.000302	0.00391	CcSEcCtD
Icosapent—Dermatitis—Mycophenolic acid—psoriasis	0.000302	0.00391	CcSEcCtD
Icosapent—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000298	0.00385	CcSEcCtD
Icosapent—TRPV1—Transmembrane transport of small molecules—CARM1—psoriasis	0.000296	0.00388	CbGpPWpGaD
Icosapent—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000296	0.00382	CcSEcCtD
Icosapent—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000295	0.00386	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—HCAR2—psoriasis	0.000295	0.00386	CbGpPWpGaD
Icosapent—Anaphylactic shock—Betamethasone—psoriasis	0.000294	0.00381	CcSEcCtD
Icosapent—Anaphylactic shock—Dexamethasone—psoriasis	0.000294	0.00381	CcSEcCtD
Icosapent—PTGS2—Overview of nanoparticle effects—CXCL8—psoriasis	0.000287	0.00376	CbGpPWpGaD
Icosapent—Dyspepsia—Triamcinolone—psoriasis	0.000286	0.00369	CcSEcCtD
Icosapent—FFAR1—GPCR downstream signaling—CCL20—psoriasis	0.000285	0.00374	CbGpPWpGaD
Icosapent—PPARG—RXR and RAR heterodimerization with other nuclear receptor—TNF—psoriasis	0.00028	0.00367	CbGpPWpGaD
Icosapent—FFAR1—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	0.000278	0.00364	CbGpPWpGaD
Icosapent—Pruritus—Cyclosporine—psoriasis	0.000274	0.00355	CcSEcCtD
Icosapent—SLC8A1—Myometrial Relaxation and Contraction Pathways—JUN—psoriasis	0.00027	0.00353	CbGpPWpGaD
Icosapent—PPARG—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	0.000269	0.00353	CbGpPWpGaD
Icosapent—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000268	0.00347	CcSEcCtD
Icosapent—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000268	0.00347	CcSEcCtD
Icosapent—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—psoriasis	0.000268	0.00351	CbGpPWpGaD
Icosapent—Pruritus—Mycophenolate mofetil—psoriasis	0.000268	0.00346	CcSEcCtD
Icosapent—Arthralgia—Prednisone—psoriasis	0.000268	0.00346	CcSEcCtD
Icosapent—PPARD—Adipogenesis—PPARG—psoriasis	0.000266	0.00349	CbGpPWpGaD
Icosapent—Malnutrition—Methotrexate—psoriasis	0.000263	0.0034	CcSEcCtD
Icosapent—SLC8A1—Myometrial Relaxation and Contraction Pathways—NFKB1—psoriasis	0.000259	0.0034	CbGpPWpGaD
Icosapent—Dyspepsia—Dexamethasone—psoriasis	0.000259	0.00335	CcSEcCtD
Icosapent—Dyspepsia—Betamethasone—psoriasis	0.000259	0.00335	CcSEcCtD
Icosapent—FFAR1—Signaling by GPCR—CCL20—psoriasis	0.000259	0.00339	CbGpPWpGaD
Icosapent—PPARG—Transcription factor regulation in adipogenesis—IL6—psoriasis	0.000258	0.00338	CbGpPWpGaD
Icosapent—Dysgeusia—Methotrexate—psoriasis	0.000257	0.00333	CcSEcCtD
Icosapent—Anaphylactic shock—Prednisone—psoriasis	0.000256	0.00332	CcSEcCtD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000256	0.00336	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TAGAP—psoriasis	0.000256	0.00335	CbGpPWpGaD
Icosapent—PPARG—Signaling events mediated by HDAC Class I—NFKBIA—psoriasis	0.000255	0.00334	CbGpPWpGaD
Icosapent—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000254	0.00329	CcSEcCtD
Icosapent—Gastrointestinal disorder—Betamethasone—psoriasis	0.000254	0.00329	CcSEcCtD
Icosapent—PPARG—Transcriptional regulation of white adipocyte differentiation—LEP—psoriasis	0.000254	0.00332	CbGpPWpGaD
Icosapent—PTGS1—Overview of nanoparticle effects—TNF—psoriasis	0.000252	0.0033	CbGpPWpGaD
Icosapent—PTGS2—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriasis	0.000247	0.00324	CbGpPWpGaD
Icosapent—Vomiting—Cyclosporine—psoriasis	0.000247	0.00319	CcSEcCtD
Icosapent—Rash—Cyclosporine—psoriasis	0.000245	0.00316	CcSEcCtD
Icosapent—Dermatitis—Cyclosporine—psoriasis	0.000244	0.00316	CcSEcCtD
Icosapent—Pruritus—Hydrocortisone—psoriasis	0.000244	0.00315	CcSEcCtD
Icosapent—Vomiting—Mycophenolate mofetil—psoriasis	0.000241	0.00311	CcSEcCtD
Icosapent—Rash—Mycophenolate mofetil—psoriasis	0.000239	0.00308	CcSEcCtD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000238	0.00312	CbGpPWpGaD
Icosapent—Dermatitis—Mycophenolate mofetil—psoriasis	0.000238	0.00308	CcSEcCtD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—psoriasis	0.000236	0.00309	CbGpPWpGaD
Icosapent—PPARD—Generic Transcription Pathway—CARM1—psoriasis	0.000234	0.00306	CbGpPWpGaD
Icosapent—Musculoskeletal discomfort—Prednisone—psoriasis	0.000234	0.00302	CcSEcCtD
Icosapent—PTGS2—S1P1 pathway—VEGFA—psoriasis	0.000233	0.00306	CbGpPWpGaD
Icosapent—FFAR1—Metabolism of proteins—ACE—psoriasis	0.000232	0.00304	CbGpPWpGaD
Icosapent—Pruritus—Triamcinolone—psoriasis	0.00023	0.00297	CcSEcCtD
Icosapent—PPARD—Wnt Signaling Pathway and Pluripotency—JUN—psoriasis	0.000229	0.003	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—SOCS1—psoriasis	0.000226	0.00296	CbGpPWpGaD
Icosapent—Dyspepsia—Prednisone—psoriasis	0.000226	0.00292	CcSEcCtD
Icosapent—Arthralgia—Methotrexate—psoriasis	0.000224	0.00289	CcSEcCtD
Icosapent—Rash—Prednisolone—psoriasis	0.000223	0.00288	CcSEcCtD
Icosapent—Dermatitis—Prednisolone—psoriasis	0.000222	0.00287	CcSEcCtD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000222	0.0029	CbGpPWpGaD
Icosapent—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—psoriasis	0.00022	0.00289	CbGpPWpGaD
Icosapent—ACSL3—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.00022	0.00289	CbGpPWpGaD
Icosapent—Constipation—Prednisone—psoriasis	0.000219	0.00284	CcSEcCtD
Icosapent—Vomiting—Hydrocortisone—psoriasis	0.000219	0.00283	CcSEcCtD
Icosapent—Rash—Hydrocortisone—psoriasis	0.000217	0.00281	CcSEcCtD
Icosapent—Dermatitis—Hydrocortisone—psoriasis	0.000217	0.00281	CcSEcCtD
Icosapent—Anaphylactic shock—Methotrexate—psoriasis	0.000214	0.00277	CcSEcCtD
Icosapent—PPARD—Metabolism—NDUFA5—psoriasis	0.000211	0.00276	CbGpPWpGaD
Icosapent—Pruritus—Betamethasone—psoriasis	0.000208	0.00269	CcSEcCtD
Icosapent—Pruritus—Dexamethasone—psoriasis	0.000208	0.00269	CcSEcCtD
Icosapent—Vomiting—Triamcinolone—psoriasis	0.000206	0.00267	CcSEcCtD
Icosapent—PTGS1—Selenium Micronutrient Network—CAT—psoriasis	0.000206	0.00269	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—CARM1—psoriasis	0.000205	0.00269	CbGpPWpGaD
Icosapent—PPARD—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	0.000205	0.00269	CbGpPWpGaD
Icosapent—Rash—Triamcinolone—psoriasis	0.000205	0.00265	CcSEcCtD
Icosapent—PTGS2—Fluticasone Propionate—Betamethasone—psoriasis	0.000205	0.0346	CbGdCrCtD
Icosapent—PTGS2—Fluticasone Propionate—Dexamethasone—psoriasis	0.000205	0.0346	CbGdCrCtD
Icosapent—Dermatitis—Triamcinolone—psoriasis	0.000204	0.00264	CcSEcCtD
Icosapent—PTGS1—Overview of nanoparticle effects—IL6—psoriasis	0.000203	0.00266	CbGpPWpGaD
Icosapent—PTGS2—Overview of nanoparticle effects—TNF—psoriasis	0.0002	0.00262	CbGpPWpGaD
Icosapent—PTGS2—Fluticasone Propionate—Triamcinolone—psoriasis	0.0002	0.0338	CbGdCrCtD
Icosapent—PPARD—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000196	0.00257	CbGpPWpGaD
Icosapent—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000195	0.00252	CcSEcCtD
Icosapent—PPARG—Gene Expression—TARS—psoriasis	0.000195	0.00256	CbGpPWpGaD
Icosapent—ACSL3—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000192	0.00251	CbGpPWpGaD
Icosapent—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—psoriasis	0.000191	0.00249	CbGpPWpGaD
Icosapent—Dyspepsia—Methotrexate—psoriasis	0.000189	0.00244	CcSEcCtD
Icosapent—Vomiting—Dexamethasone—psoriasis	0.000187	0.00242	CcSEcCtD
Icosapent—Vomiting—Betamethasone—psoriasis	0.000187	0.00242	CcSEcCtD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000186	0.00243	CbGpPWpGaD
Icosapent—Rash—Dexamethasone—psoriasis	0.000186	0.0024	CcSEcCtD
Icosapent—Rash—Betamethasone—psoriasis	0.000186	0.0024	CcSEcCtD
Icosapent—Dermatitis—Betamethasone—psoriasis	0.000186	0.0024	CcSEcCtD
Icosapent—Dermatitis—Dexamethasone—psoriasis	0.000186	0.0024	CcSEcCtD
Icosapent—Gastrointestinal disorder—Methotrexate—psoriasis	0.000185	0.00239	CcSEcCtD
Icosapent—FADS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000185	0.00242	CbGpPWpGaD
Icosapent—Pruritus—Prednisone—psoriasis	0.000181	0.00235	CcSEcCtD
Icosapent—PPARD—Metabolism—CYP2S1—psoriasis	0.000179	0.00235	CbGpPWpGaD
Icosapent—FFAR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	0.000179	0.00234	CbGpPWpGaD
Icosapent—PPARG—Regulation of retinoblastoma protein—JUN—psoriasis	0.000177	0.00232	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—psoriasis	0.000174	0.00227	CbGpPWpGaD
Icosapent—FADS1—Metabolism—CARM1—psoriasis	0.000172	0.00225	CbGpPWpGaD
Icosapent—ACSL4—Metabolism of lipids and lipoproteins—APOE—psoriasis	0.000167	0.00219	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—LEP—psoriasis	0.000167	0.00219	CbGpPWpGaD
Icosapent—PPARG—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	0.000166	0.00217	CbGpPWpGaD
Icosapent—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—psoriasis	0.000164	0.00215	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—STAT3—psoriasis	0.000163	0.00214	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—CRP—psoriasis	0.000163	0.00214	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—CAT—psoriasis	0.000163	0.00214	CbGpPWpGaD
Icosapent—Vomiting—Prednisone—psoriasis	0.000163	0.00211	CcSEcCtD
Icosapent—PPARG—Signaling events mediated by HDAC Class I—NFKB1—psoriasis	0.000163	0.00213	CbGpPWpGaD
Icosapent—SLC8A1—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	0.000163	0.00213	CbGpPWpGaD
Icosapent—Rash—Prednisone—psoriasis	0.000162	0.00209	CcSEcCtD
Icosapent—Dermatitis—Prednisone—psoriasis	0.000162	0.00209	CcSEcCtD
Icosapent—PTGS2—Overview of nanoparticle effects—IL6—psoriasis	0.000161	0.00211	CbGpPWpGaD
Icosapent—FADS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000161	0.00211	CbGpPWpGaD
Icosapent—SLC8A1—Hemostasis—NOS2—psoriasis	0.000158	0.00207	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—CARM1—psoriasis	0.000156	0.00204	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—CARM1—psoriasis	0.000156	0.00204	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—CCL20—psoriasis	0.000153	0.002	CbGpPWpGaD
Icosapent—Pruritus—Methotrexate—psoriasis	0.000152	0.00196	CcSEcCtD
Icosapent—PPARD—Wnt Signaling Pathway and Pluripotency—TP53—psoriasis	0.000151	0.00198	CbGpPWpGaD
Icosapent—PPARG—Transcriptional regulation of white adipocyte differentiation—NFKB1—psoriasis	0.000151	0.00198	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—ICAM1—psoriasis	0.00015	0.00197	CbGpPWpGaD
Icosapent—PPARG—Signaling events mediated by HDAC Class I—STAT3—psoriasis	0.000146	0.00192	CbGpPWpGaD
Icosapent—ACSL4—Metabolism of lipids and lipoproteins—PPARG—psoriasis	0.000146	0.0019	CbGpPWpGaD
Icosapent—FFAR1—Metabolism of proteins—LEP—psoriasis	0.000144	0.00189	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—psoriasis	0.000143	0.00187	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—TNF—psoriasis	0.000141	0.00185	CbGpPWpGaD
Icosapent—PPARD—Generic Transcription Pathway—VDR—psoriasis	0.00014	0.00183	CbGpPWpGaD
Icosapent—FFAR1—GPCR ligand binding—CXCL8—psoriasis	0.000136	0.00179	CbGpPWpGaD
Icosapent—Vomiting—Methotrexate—psoriasis	0.000136	0.00176	CcSEcCtD
Icosapent—FFAR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	0.000136	0.00178	CbGpPWpGaD
Icosapent—Rash—Methotrexate—psoriasis	0.000135	0.00175	CcSEcCtD
Icosapent—Dermatitis—Methotrexate—psoriasis	0.000135	0.00175	CcSEcCtD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CXCL8—psoriasis	0.000133	0.00174	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—CRP—psoriasis	0.00013	0.0017	CbGpPWpGaD
Icosapent—PPARG—Generic Transcription Pathway—CARM1—psoriasis	0.000128	0.00167	CbGpPWpGaD
Icosapent—PTGS2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000127	0.00166	CbGpPWpGaD
Icosapent—PPARG—Signaling events mediated by HDAC Class I—TNF—psoriasis	0.000127	0.00166	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—CAT—psoriasis	0.000126	0.00165	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—psoriasis	0.000123	0.00161	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—CARM1—psoriasis	0.00012	0.00157	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—ICAM1—psoriasis	0.000119	0.00156	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—IL4—psoriasis	0.000119	0.00155	CbGpPWpGaD
Icosapent—PPARG—Circadian rythm related genes—LEP—psoriasis	0.000118	0.00154	CbGpPWpGaD
Icosapent—PPARG—Transcriptional regulation of white adipocyte differentiation—TNF—psoriasis	0.000117	0.00154	CbGpPWpGaD
Icosapent—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	0.000115	0.00151	CbGpPWpGaD
Icosapent—PPARG—Metabolism—NDUFA5—psoriasis	0.000115	0.00151	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—IFNG—psoriasis	0.000114	0.0015	CbGpPWpGaD
Icosapent—PPARD—Adipogenesis—IL6—psoriasis	0.000114	0.00149	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—CARM1—psoriasis	0.000113	0.00147	CbGpPWpGaD
Icosapent—PPARG—Circadian rythm related genes—NOS2—psoriasis	0.00011	0.00144	CbGpPWpGaD
Icosapent—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—psoriasis	0.000108	0.00142	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—CARM1—psoriasis	0.000107	0.0014	CbGpPWpGaD
Icosapent—FADS1—Metabolism—CAT—psoriasis	0.000106	0.00139	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—LEP—psoriasis	0.0001	0.00131	CbGpPWpGaD
Icosapent—PTGS2—Aryl Hydrocarbon Receptor—TNF—psoriasis	9.86e-05	0.00129	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—APOE—psoriasis	9.82e-05	0.00129	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CYP2S1—psoriasis	9.78e-05	0.00128	CbGpPWpGaD
Icosapent—PPARD—Generic Transcription Pathway—PPARG—psoriasis	9.73e-05	0.00127	CbGpPWpGaD
Icosapent—FFAR1—Metabolism of proteins—CXCL8—psoriasis	9.59e-05	0.00126	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—CAT—psoriasis	9.57e-05	0.00125	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—CAT—psoriasis	9.57e-05	0.00125	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—NFKB1—psoriasis	9.51e-05	0.00124	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—ICAM1—psoriasis	9.43e-05	0.00123	CbGpPWpGaD
Icosapent—PPARD—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.39e-05	0.00123	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—NOS2—psoriasis	9.35e-05	0.00122	CbGpPWpGaD
Icosapent—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriasis	9.23e-05	0.00121	CbGpPWpGaD
Icosapent—SLC8A1—Hemostasis—VEGFA—psoriasis	9.14e-05	0.0012	CbGpPWpGaD
Icosapent—PTGS2—C-MYB transcription factor network—CD4—psoriasis	9.09e-05	0.00119	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—IFNG—psoriasis	9.07e-05	0.00119	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—STAT3—psoriasis	8.93e-05	0.00117	CbGpPWpGaD
Icosapent—PPARD—Metabolism—CARM1—psoriasis	8.75e-05	0.00115	CbGpPWpGaD
Icosapent—ACSL3—Metabolism—PPARG—psoriasis	8.55e-05	0.00112	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—SOCS1—psoriasis	8.43e-05	0.0011	CbGpPWpGaD
Icosapent—FADS1—Metabolism—APOE—psoriasis	8.23e-05	0.00108	CbGpPWpGaD
Icosapent—PPARD—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.18e-05	0.00107	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—NDUFA5—psoriasis	8.06e-05	0.00106	CbGpPWpGaD
Icosapent—FFAR1—Signaling by GPCR—TYK2—psoriasis	8.04e-05	0.00105	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—TNF—psoriasis	7.73e-05	0.00101	CbGpPWpGaD
Icosapent—FFAR1—GPCR downstream signaling—CXCL8—psoriasis	7.71e-05	0.00101	CbGpPWpGaD
Icosapent—PPARG—Generic Transcription Pathway—VDR—psoriasis	7.62e-05	0.000997	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	7.57e-05	0.000991	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—NFKB1—psoriasis	7.55e-05	0.000988	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	7.51e-05	0.000984	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—APOE—psoriasis	7.44e-05	0.000974	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—APOE—psoriasis	7.44e-05	0.000974	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—TNF—psoriasis	7.39e-05	0.000968	CbGpPWpGaD
Icosapent—PPARG—Circadian rythm related genes—JUN—psoriasis	7.28e-05	0.000953	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—IFNG—psoriasis	7.17e-05	0.000939	CbGpPWpGaD
Icosapent—FADS1—Metabolism—PPARG—psoriasis	7.17e-05	0.000938	CbGpPWpGaD
Icosapent—FFAR1—Signaling by GPCR—CXCL8—psoriasis	7e-05	0.000916	CbGpPWpGaD
Icosapent—SLC8A1—Hemostasis—TP53—psoriasis	6.91e-05	0.000904	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CYP2S1—psoriasis	6.85e-05	0.000897	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—VDR—psoriasis	6.72e-05	0.00088	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—CXCL8—psoriasis	6.67e-05	0.000873	CbGpPWpGaD
Icosapent—ACSL4—Metabolism—PPARG—psoriasis	6.48e-05	0.000848	CbGpPWpGaD
Icosapent—FFAR1—Metabolism—PPARG—psoriasis	6.48e-05	0.000848	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—NDUFA5—psoriasis	6.4e-05	0.000838	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	6.36e-05	0.000833	CbGpPWpGaD
Icosapent—PPARG—Adipogenesis—IL6—psoriasis	6.23e-05	0.000816	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—LEP—psoriasis	6.22e-05	0.000814	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—APOE—psoriasis	6.22e-05	0.000814	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—CARM1—psoriasis	6.14e-05	0.000804	CbGpPWpGaD
Icosapent—PTGS1—Selenium Micronutrient Network—IL6—psoriasis	5.97e-05	0.000781	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	5.97e-05	0.000781	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—TNF—psoriasis	5.87e-05	0.000768	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—NFKBIA—psoriasis	5.8e-05	0.000759	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—LEP—psoriasis	5.74e-05	0.000751	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CYP2S1—psoriasis	5.44e-05	0.000712	CbGpPWpGaD
Icosapent—PPARD—Metabolism—CAT—psoriasis	5.38e-05	0.000704	CbGpPWpGaD
Icosapent—PPARG—Metabolism of lipids and lipoproteins—APOE—psoriasis	5.13e-05	0.000671	CbGpPWpGaD
Icosapent—PPARG—Circadian rythm related genes—TP53—psoriasis	4.81e-05	0.000629	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CARM1—psoriasis	4.78e-05	0.000625	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TYK2—psoriasis	4.75e-05	0.000622	CbGpPWpGaD
Icosapent—PTGS2—Selenium Micronutrient Network—IL6—psoriasis	4.74e-05	0.00062	CbGpPWpGaD
Icosapent—PPARD—Gene Expression—PPARG—psoriasis	4.68e-05	0.000613	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—TNF—psoriasis	4.64e-05	0.000608	CbGpPWpGaD
Icosapent—PPARG—Circadian rythm related genes—IL6—psoriasis	4.4e-05	0.000576	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—TYK2—psoriasis	4.38e-05	0.000574	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	4.22e-05	0.000552	CbGpPWpGaD
Icosapent—PPARD—Metabolism—APOE—psoriasis	4.18e-05	0.000547	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—CXCL8—psoriasis	4.13e-05	0.000541	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—TP53—psoriasis	4.09e-05	0.000536	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	4.06e-05	0.000532	CbGpPWpGaD
Icosapent—FFAR1—Signaling by GPCR—IL6—psoriasis	3.93e-05	0.000515	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—JUN—psoriasis	3.84e-05	0.000503	CbGpPWpGaD
Icosapent—PTGS2—Spinal Cord Injury—IL6—psoriasis	3.75e-05	0.00049	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—NFKB1—psoriasis	3.7e-05	0.000484	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	3.68e-05	0.000482	CbGpPWpGaD
Icosapent—PPARG—Gene Expression—VDR—psoriasis	3.67e-05	0.00048	CbGpPWpGaD
Icosapent—PPARD—Metabolism—PPARG—psoriasis	3.64e-05	0.000477	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—APOE—psoriasis	3.59e-05	0.00047	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—NFKB1—psoriasis	3.41e-05	0.000447	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—VEGFA—psoriasis	3.36e-05	0.00044	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CARM1—psoriasis	3.35e-05	0.000438	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—STAT3—psoriasis	3.32e-05	0.000435	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	3.16e-05	0.000413	CbGpPWpGaD
Icosapent—PTGS1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.13e-05	0.000409	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—VEGFA—psoriasis	3.1e-05	0.000406	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—STAT3—psoriasis	3.07e-05	0.000402	CbGpPWpGaD
Icosapent—PPARG—Metabolism—CAT—psoriasis	2.94e-05	0.000385	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.85e-05	0.000373	CbGpPWpGaD
Icosapent—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	2.78e-05	0.000364	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CARM1—psoriasis	2.66e-05	0.000348	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—TNF—psoriasis	2.66e-05	0.000348	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—TP53—psoriasis	2.54e-05	0.000332	CbGpPWpGaD
Icosapent—PTGS2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	2.48e-05	0.000325	CbGpPWpGaD
Icosapent—FFAR1—Signaling Pathways—IL6—psoriasis	2.32e-05	0.000304	CbGpPWpGaD
Icosapent—PPARG—Metabolism—APOE—psoriasis	2.28e-05	0.000299	CbGpPWpGaD
Icosapent—PPARG—Developmental Biology—IL6—psoriasis	2.14e-05	0.000281	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—CAT—psoriasis	2.06e-05	0.000269	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—CAT—psoriasis	1.63e-05	0.000214	CbGpPWpGaD
Icosapent—PTGS2—Disease—HLA-A—psoriasis	1.62e-05	0.000213	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—APOE—psoriasis	1.6e-05	0.000209	CbGpPWpGaD
Icosapent—PTGS2—Disease—APOE—psoriasis	1.52e-05	0.000198	CbGpPWpGaD
Icosapent—PTGS2—Disease—NOS2—psoriasis	1.41e-05	0.000185	CbGpPWpGaD
Icosapent—PTGS1—Metabolism—PPARG—psoriasis	1.39e-05	0.000182	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—APOE—psoriasis	1.27e-05	0.000166	CbGpPWpGaD
Icosapent—PTGS2—Disease—TYK2—psoriasis	1.16e-05	0.000151	CbGpPWpGaD
Icosapent—PTGS2—Metabolism—PPARG—psoriasis	1.11e-05	0.000145	CbGpPWpGaD
Icosapent—PTGS2—Disease—CD4—psoriasis	1.05e-05	0.000137	CbGpPWpGaD
Icosapent—PTGS2—Disease—STAT3—psoriasis	8.1e-06	0.000106	CbGpPWpGaD
Icosapent—PTGS2—Disease—IL6—psoriasis	5.66e-06	7.41e-05	CbGpPWpGaD
